Study on the Classification, Causality, Preventability and Severity of Adverse Drug Reaction Using Spontaneous Reporting System in Hospitalized Patients
Abstract
:1. Introduction
2. Methods
2.1. Statistical Analysis
2.2. Ethical Approval
3. Results
4. Discussion
5. Conclusions
Supplementary Materials
Author Contributions
Funding
Acknowledgments
Conflicts of Interest
References
- Arulmani, R.; Rajendran, S.D.; Suresh, B. Adverse drug reaction monitoring in a secondary care hospital in south India. Br. J. Clin. Pharmacol. 2008, 65, 210–216. [Google Scholar] [CrossRef] [PubMed]
- Wester, K.; Jonsson, A.K.; Spigset, O.; Druid, H.; Hagg, S. Incidence of fatal adverse drug reactions: A population based study. Br. J. Clin. Pharmacol. 2008, 65, 573–579. [Google Scholar] [CrossRef] [PubMed]
- Einarson, T.R. Drug-related hospital admissions. Ann. Pharmacother. 1993, 27, 832–840. [Google Scholar] [CrossRef] [PubMed]
- Lazarou, J.; Pomeranz, B.H.; Corey, P.N. Incidence of adverse drug reactions in hospitalized patients: A meta-analysis of prospective studies. JAMA 1998, 279, 1200–1205. [Google Scholar] [CrossRef] [PubMed]
- Moore, N.; Lecointre, D.; Noblet, C.; Mabille, M. Frequency and cost of serious adverse drug reactions in a department of general medicine. Br. J. Clin. Pharmacol. 1998, 45, 301–308. [Google Scholar] [CrossRef] [PubMed]
- Davies, E.C.; Green, C.F.; Taylor, S.; Williamson, P.R.; Mottram, D.R.; Pirmohamed, M. Adverse drug reactions in hospital in-patients: A prospective analysis of 3695 patient-episodes. PLoS ONE 2009, 4, e4439. [Google Scholar] [CrossRef] [PubMed]
- Wu, C.; Bell, C.M.; Wodchis, W.P. Incidence and economic burden of adverse drug reactions among elderly patients in ontario emergency departments: A retrospective study. Drug Saf. 2012, 35, 769–781. [Google Scholar] [CrossRef] [PubMed]
- World health organization. International drug monitoring: The role of national centres. Report of a who meeting. World Health Organ. Tech. Rep. Ser. 1972, 498, 1–25. [Google Scholar]
- Wills, S.; Brown, D. A proposed new means of classifying adverse reactions to medicines. Pharm. J. 1999, 262, 163–165. [Google Scholar]
- Krahenbuhl-Melcher, A.; Schlienger, R.; Lampert, M.; Haschke, M.; Drewe, J.; Krahenbuhl, S. Drug-related problems in hospitals: A review of the recent literature. Drug Saf. 2007, 30, 379–407. [Google Scholar] [CrossRef] [PubMed]
- Patel, T.K.; Patel, P.B. Incidence of adverse drug reactions in Indian hospitals: A systematic review of prospective studies. Curr. Drug Saf. 2016, 11, 128–136. [Google Scholar] [CrossRef] [PubMed]
- Alsaleh, F.M.; Alzaid, S.W.; Abahussain, E.A.; Bayoud, T.; Lemay, J. Knowledge, attitude and practices of pharmacovigilance and adverse drug reaction reporting among pharmacists working in secondary and tertiary governmental hospitals in Kuwait. Saudi Pharm. J. 2017, 25, 830–837. [Google Scholar] [CrossRef] [PubMed]
- Schneeweiss, S.; Hasford, J.; Gottler, M.; Hoffmann, A.; Riethling, A.K.; Avorn, J. Admissions caused by adverse drug events to internal medicine and emergency departments in hospitals: A longitudinal population-based study. Eur. J. Clin. Pharmacol. 2002, 58, 285–291. [Google Scholar] [CrossRef] [PubMed]
- Hallas, J.; Gram, L.F.; Grodum, E.; Damsbo, N.; Brosen, K.; Haghfelt, T.; Harvald, B.; Beck-Nielsen, J.; Worm, J.; Jensen, K.B.; et al. Drug related admissions to medical wards: A population based survey. Br. J. Clin. Pharmacol. 1992, 33, 61–68. [Google Scholar] [CrossRef] [PubMed]
- Lihite, R.J.; Lahkar, M.; Das, S.; Hazarika, D.; Kotni, M.; Maqbool, M.; Phukan, S. A study on adverse drug reactions in a tertiary care hospital of northeast India. Alex. J. Med. 2017, 53, 151–156. [Google Scholar] [CrossRef]
- Sriram, S.; Ghasemi, A.; Ramasamy, R.; Devi, M.; Balasubramanian, R.; Ravi, T.K.; Sabzghabaee, A.M. Prevalence of adverse drug reactions at a private tertiary care hospital in south India. J. Res. Med. Sci. Off. J. Isfahan Univ. Med. Sci. 2011, 16, 16–25. [Google Scholar]
- Stricker, B.H.; Psaty, B.M. Detection, verification, and quantification of adverse drug reactions. BMJ 2004, 329, 44–47. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Naranjo, C.A.; Busto, U.; Sellers, E.M.; Sandor, P.; Ruiz, I.; Roberts, E.A.; Janecek, E.; Domecq, C.; Greenblatt, D.J. A method for estimating the probability of adverse drug reactions. Clin. Pharmacol. Ther. 1981, 30, 239–245. [Google Scholar] [CrossRef] [PubMed]
- Schumock, G.T.; Thornton, J.P. Focusing on the preventability of adverse drug reactions. Hosp. Pharm. 1992, 27, 538. [Google Scholar] [PubMed]
- Hartwig, S.C.; Siegel, J.; Schneider, P.J. Preventability and severity assessment in reporting adverse drug reactions. Am. J. Hosp. Pharm. 1992, 49, 2229–2232. [Google Scholar] [PubMed]
- Pal, S.N.; Duncombe, C.; Falzon, D.; Olsson, S. Who strategy for collecting safety data in public health programmes: Complementing spontaneous reporting systems. Drug Saf. 2013, 36, 75–81. [Google Scholar] [CrossRef] [PubMed]
- Bouvy, J.C.; De Bruin, M.L.; Koopmanschap, M.A. Epidemiology of adverse drug reactions in europe: A review of recent observational studies. Drug Saf. 2015, 38, 437–453. [Google Scholar] [CrossRef] [PubMed]
- Jha, N.; Bajracharya, O.; Namgyal, T. Prevalence of adverse drug reactions with commonly prescribed drugs in different hospitals of kathmandu valley. Kathmandu Univ. Med. J. (KUMJ) 2007, 5, 504–510. [Google Scholar]
- Palleria, C.; Leporini, C.; Chimirri, S.; Marrazzo, G.; Sacchetta, S.; Bruno, L.; Lista, R.M.; Staltari, O.; Scuteri, A.; Scicchitano, F.; et al. Limitations and obstacles of the spontaneous adverse drugs reactions reporting: Two “challenging” case reports. J. Pharmacol. Pharmacother. 2013, 4, S66–S72. [Google Scholar] [PubMed]
- Mazzitello, C.; Esposito, S.; De Francesco, A.E.; Capuano, A.; Russo, E.; De Sarro, G. Pharmacovigilance in Italy: An overview. J. Pharmacol. Pharmacother. 2013, 4, S20–S28. [Google Scholar] [PubMed]
- Fletcher, A.P. Spontaneous adverse drug reaction reporting vs. event monitoring: A comparison. J. R. Soc. Med. 1991, 84, 341–344. [Google Scholar] [CrossRef] [PubMed]
- Mouton, J.P.; Mehta, U.; Rossiter, D.P.; Maartens, G.; Cohen, K. Interrater agreement of two adverse drug reaction causality assessment methods: A randomised comparison of the liverpool adverse drug reaction causality assessment tool and the world health organization-uppsala monitoring centre system. PLoS ONE 2017, 12, e0172830. [Google Scholar] [CrossRef] [PubMed]
- Gallagher, R.M.; Kirkham, J.J.; Mason, J.R.; Bird, K.A.; Williamson, P.R.; Nunn, A.J.; Turner, M.A.; Smyth, R.L.; Pirmohamed, M. Development and inter-rater reliability of the liverpool adverse drug reaction causality assessment tool. PLoS ONE 2011, 6, e28096. [Google Scholar] [CrossRef] [PubMed]
- Lavan, A.H.; Gallagher, P. Predicting risk of adverse drug reactions in older adults. Ther. Adv. Drug Saf. 2016, 7, 11–22. [Google Scholar] [CrossRef] [PubMed]
- Beijer, H.J.; de Blaey, C.J. Hospitalisations caused by adverse drug reactions (adr): A meta-analysis of observational studies. Pharm. World Sci. PWS 2002, 24, 46–54. [Google Scholar] [CrossRef] [PubMed]
- Pirmohamed, M.; James, S.; Meakin, S.; Green, C.; Scott, A.K.; Walley, T.J.; Farrar, K.; Park, B.K.; Breckenridge, A.M. Adverse drug reactions as cause of admission to hospital: Prospective analysis of 18,820 patients. BMJ 2004, 329, 15–19. [Google Scholar] [CrossRef] [PubMed]
- Shehab, N.; Patel, P.R.; Srinivasan, A.; Budnitz, D.S. Emergency department visits for antibiotic-associated adverse events. Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am. 2008, 47, 735–743. [Google Scholar] [CrossRef] [PubMed]
- Aljadhey, H.; Mahmoud, M.A.; Ahmed, Y.; Sultana, R.; Zouein, S.; Alshanawani, S.; Mayet, A.; Alshaikh, M.K.; Kalagi, N.; Al Tawil, E.; et al. Incidence of adverse drug events in public and private hospitals in Riyadh, Saudi Arabia: The (adesa) prospective cohort study. BMJ Open 2016, 6, e010831. [Google Scholar] [CrossRef] [PubMed]
- Jose, J.; Rao, P.G. Pattern of adverse drug reactions notified by spontaneous reporting in an Indian tertiary care teaching hospital. Pharmacol. Res. 2006, 54, 226–233. [Google Scholar] [CrossRef] [PubMed]
- Chan, M.; Nicklason, F.; Vial, J.H. Adverse drug events as a cause of hospital admission in the elderly. Intern. Med. J. 2001, 31, 199–205. [Google Scholar] [CrossRef] [PubMed]
- Hug, B.L.; Witkowski, D.J.; Sox, C.M.; Keohane, C.A.; Seger, D.L.; Yoon, C.; Matheny, M.E.; Bates, D.W. Adverse drug event rates in six community hospitals and the potential impact of computerized physician order entry for prevention. J. Gen. Intern. Med. 2010, 25, 31–38. [Google Scholar] [CrossRef] [PubMed]
- Kucukarslan, S.N.; Peters, M.; Mlynarek, M.; Nafziger, D.A. Pharmacists on rounding teams reduce preventable adverse drug events in hospital general medicine units. Arch. Intern. Med. 2003, 163, 2014–2018. [Google Scholar] [CrossRef] [PubMed]
- Leape, L.L.; Cullen, D.J.; Clapp, M.D.; Burdick, E.; Demonaco, H.J.; Erickson, J.I.; Bates, D.W. Pharmacist participation on physician rounds and adverse drug events in the intensive care unit. JAMA 1999, 282, 267–270. [Google Scholar] [CrossRef] [PubMed]
- Splawski, J.; Minger, H. Value of the pharmacist in the medication reconciliation process. Pharm. Ther. 2016, 41, 176–178. [Google Scholar]
- Benkirane, R.; Soulaymani-Bencheikh, R.; Khattabi, A.; Benabdallah, G.; Alj, L.; Sefiani, H.; Hedna, K.; Ouammi, L.; Olsson, S.; Pal, S.N. Assessment of a new instrument for detecting preventable adverse drug reactions. Drug Saf. 2015, 38, 383–393. [Google Scholar] [CrossRef] [PubMed]
- Comfort, S.; Dorrell, D.; Meireis, S.; Fine, J. Modified NARanjo causality scale for ICSRs (MONARCSI): A decision support tool for safety scientists. Drug Saf. 2018. [Google Scholar] [CrossRef] [PubMed]
Demographic Characteristics | Number of Patients with ADR | Percentage (%) | |
---|---|---|---|
Sex * | Male | 21 | 42.9 |
Female | 28 | 57.1 | |
Age (years) * | ≤18 | 5 | 10.2 |
19–64 | 23 | 46.9 | |
≥ 65 | 21 | 42.9 | |
ADR per patient | At least one | 48 | 98.0 |
Greater than one | 1 | 2.0 |
Parameter | Frequency (n = 51) |
---|---|
Classification (Wills and Brown Classification) | |
Type A-Augmented | 39 (76.5%) |
Type B-Bugs | 0 |
Type C-Chemical | 1 (2.0%) |
Type D-Delivery | 1 (2.0%) |
Type E-Exit | 0 |
Type F-Familial | 0 |
Type G-Genotoxicity | 0 |
Type H-Hypersensitivity | 10 (19.6%) |
Type U-Unclassified | 0 |
Causality (Naranjo’s algorithm scale) | |
Probable | 26 (51.0%) |
Possible | 25 (49.0%) |
Definite | 0 |
Unlikely | 0 |
Severity (Modified Hartwig and Siegel scale) | |
Mild-Level 1 | 0 |
Mild-Level 2 | 11 (21.6%) |
Moderate-Level 3 | 25 (49.0%) |
Moderate-Level 4 (a) | 8 (15.7%) |
Moderate-Level 4 (b) | 2 (3.9%) |
Severe-Level 5 | 5 (9.8%) |
Severe-Level 6 | 0 |
Severe-Level 7 | 0 |
Preventability (Modified Schumock and Thornton scale) | |
Definitely preventable | 15 (29.4%) |
Probably preventable | 19 (37.3%) |
Not preventable | 17 (33.3%) |
Predictability (based on the incidence rate of the reported ADRs as per product information and relevant literatures) | |
Predictable | 28 (54.9%) |
Unpredictable | 23 (45.1%) |
Management | |
Stopped the medication | 15 (29.4%) |
Substituted another drug | 15 (29.4%) |
Reduced the dose | 12 (23.5%) |
Added another drug | 9 (17.7%) |
Outcome of management | |
Recovered | 30 (58.8%) |
Recovering | 21 (41.2%) |
Fatal | 0 |
Drug Class (n, %) | Medication | Reaction Details |
---|---|---|
Antibiotic (14, 27.5) | Ciprofloxacin | Redness and itching |
Metronidazole | Vomiting, Thrombophlebitis | |
Ofloxacin | Seizure | |
Amoxicillin + Clavulanic acid | Fever | |
Cefoperazone + Sulbactam | Inflammation of vein, Diarrhea | |
Rifampicin + Isoniazid + Pyrazinamide + Ethambutol | Nausea | |
Amoxicillin | Colitis | |
Cefotaxime | Itching and rash | |
Ceftazidime + Tobramycin | Itching and rash | |
Ceftriaxone | Thrombocytosis | |
Antiepileptic (11, 21.6) | Sodium valproate | Alopecia |
Carbamazepine | Fatigue, Blurred vision, Ataxia | |
Clobazam | Memory loss, Hypersomnia | |
Topiramate | Anorexia | |
Levetiracetam | Decreased appetite | |
Oxcarbamazepine | Hypersomnia and fatigue | |
Antihypertensive (4, 7.8) | Bisoprolol, Carvedilol | Increased breathlessness and QT prolongation |
Furosemide | Hyponatremia, Hypokalemia | |
Telmisartan, Cilnidipine | Hypotension | |
NSAID (3, 5.9) | Ketorolac | Periorbital edema, Redness and itching |
Mefenamic acid | Gastritis | |
Antipsychotics (2, 3.9) | Olanzapine + Quetiapine | Extra pyramidal symptoms |
Quetiapine | Fatigue | |
Statin (2, 3.9) | Atorvastatin | Myopathy |
Rosuvastatin | Myopathy | |
Antifungal (2, 3.9) | Amphotericin B | Renal failure, Diarrhea |
Anesthetic (3, 5.9) | Bupivacaine | Post spinal headache * |
Cognition enhancer (1, 2.0) | Cerebroprotein hydrolysate | Itching |
Antidiabetic (1, 2.0) | Glimepiride | Hypoglycemia |
Anti-craving agent (1, 2.0) | Acamprosate | Diarrhea |
Antiplatelet (1, 2.0) | Clopidogrel | Abdominal pain |
Diagnostic agent (1, 2.0) | Iopromide | Anaphylactic shock |
Antianginal (1, 2.0) | Isosorbide dinitrate | Hypotension |
Antineoplastic (1, 2.0) | Rituximab | Shivering and breathing difficulty |
Others (3, 5.9) | Prazosin | Generalized maculopapular rashes |
Paracetamol | Nephropathy | |
Insulin, Furosemide | Hypokalemia |
© 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
Share and Cite
Sundaran, S.; Udayan, A.; Hareendranath, K.; Eliyas, B.; Ganesan, B.; Hassan, A.; Subash, R.; Palakkal, V.; Salahudeen, M.S. Study on the Classification, Causality, Preventability and Severity of Adverse Drug Reaction Using Spontaneous Reporting System in Hospitalized Patients. Pharmacy 2018, 6, 108. https://doi.org/10.3390/pharmacy6040108
Sundaran S, Udayan A, Hareendranath K, Eliyas B, Ganesan B, Hassan A, Subash R, Palakkal V, Salahudeen MS. Study on the Classification, Causality, Preventability and Severity of Adverse Drug Reaction Using Spontaneous Reporting System in Hospitalized Patients. Pharmacy. 2018; 6(4):108. https://doi.org/10.3390/pharmacy6040108
Chicago/Turabian StyleSundaran, Siraj, Anjali Udayan, Keerthi Hareendranath, Basil Eliyas, Babu Ganesan, Ashik Hassan, Rajesh Subash, Vishnu Palakkal, and Mohammed Saji Salahudeen. 2018. "Study on the Classification, Causality, Preventability and Severity of Adverse Drug Reaction Using Spontaneous Reporting System in Hospitalized Patients" Pharmacy 6, no. 4: 108. https://doi.org/10.3390/pharmacy6040108
APA StyleSundaran, S., Udayan, A., Hareendranath, K., Eliyas, B., Ganesan, B., Hassan, A., Subash, R., Palakkal, V., & Salahudeen, M. S. (2018). Study on the Classification, Causality, Preventability and Severity of Adverse Drug Reaction Using Spontaneous Reporting System in Hospitalized Patients. Pharmacy, 6(4), 108. https://doi.org/10.3390/pharmacy6040108